Please select the option that best describes you:

Would you offer imatinib to a patient with a high risk GIST (> 10 cm, low Ki-67, s/p complete resection) who initially declined adjuvant therapy, but is now interested 14 months post surgery?   

Is there any data to suggest delayed initiation of adjuvant treatment would be beneficial? Or would close surveillance be reasonable? Patient is asymptomatic and recent surveillance imaging was negative. 



Answer from: Medical Oncologist at Academic Institution
Sign in or Register to read more